Brainsway Ltd. (BWAY)
| Market Cap | 145.56M |
| Revenue (ttm) | 23.10M |
| Net Income (ttm) | -10.33M |
| Shares Out | 15.88M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $8.92 |
| Previous Close | $9.06 |
| Change ($) | -0.14 |
| Change (%) | -1.55% |
| Day's Open | 8.97 |
| Day's Range | 8.74 - 9.34 |
| Day's Volume | 154,366 |
| 52-Week Range | 5.52 - 11.04 |
The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction
Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET
CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today a...
CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain dis...
CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain diso...
CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disor...
CRESSKILL, N.J. and JERUSALEM, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of b...
Following Historic Abraham Accords, Israel's Deep Transcranial Magnetic Stimulation (Deep TMS) Treatment to Come to the United Arab Emirates Following Historic Abraham Accords, Israel's Deep Transcrania...
FDA clearance for smoking cessation moves Brainsway towards a portfolio of neurological disorder treatments and extends the company's competitive advantage. The publication of positive real-world result...
Brainsway Ltd. (BWAY) CEO Chris von Jako on Q3 2020 Results - Earnings Call Transcript
Monday, November 23, 2020, at 10:00 AM Eastern Time Monday, November 23, 2020, at 10:00 AM Eastern Time
CRESSKILL, N.J. and JERUSALEM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disor...
In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder In conjunction with OCD Awareness We...
Deep TMS highlighted in 10 presentation posters at annual session Deep TMS highlighted in 10 presentation posters at annual session
CRESSKILL, N.J. and JERUSALEM, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of...
As of late, it has definitely been a great time to be an investor in Brainsway.
CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain d...
Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Brainsway’s current valuation is low as a result of a decline in revenue due to COVID-19 lockdowns.s
Brainsway (BWAY) news for Monday includes approval from the U.S. Food & Drug Administration (FDA) sending BWAY stock higher.
Company Intends to Execute a Controlled U.S. Market Release in Early 2021
BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q2 2020 Results - Earnings Call Transcript
Shares of Brainsway (NASDAQ:BWAY) remained unaffected after the company reported Q2 results.
CRESSKILL, N.J. and JERUSALEM, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of ...
CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of b...
PATTERSON, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, toda...
BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q1 2020 Results - Earnings Call Transcript
PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, June 24th, by BrainsWay Ltd. (NASDAQ & TASE: BWAY), please note that, in the...
PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain di...
New site features user-friendly layout, easy access to resources, and tools for those affected by COVID-19 New site features user-friendly layout, easy access to resources, and tools for those affected ...
PATTERSON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today ...
Hadar Levy Promoted to Senior Vice President and General Manager of North America
BrainsWay will donate $1 per entry to the National Alliance of Mental Illness (NAMI) and each entry will be entered for a chance to win a $250 Amazon gift card BrainsWay will donate $1 per entry to the ...
PATTERSON, N.J., April 13, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, toda...
Brainsway Continues Growth Trajectory While Conserving Cash
Brainsway Ltd. (BWAY) CEO Christopher von Jako on Q4 2019 Results - Earnings Call Transcript
Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s H6-coil, which correlate with observed improvement in ADHD symptoms
Lushi also to serve on Company’s audit committee Lushi also to serve on Company’s audit committee
Company to discontinue funding of study following insufficient demonstration of efficacy Company to discontinue funding of study following insufficient demonstration of efficacy
Shares of Brainsway are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers.
Primary and secondary endpoint achieved with statistical significance
Brainsway Ltd. (BWAY) CEO David Zacut on Q3 2019 Results - Earnings Call Transcript
JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of...
JERUSALEM, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today that it will be exhib...
Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now available in Greenwood Village Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now...
BrainsWay is a technology leader in the transcranial magnetic stimulation market which holds significant potential if it becomes widely accepted by doctors and patients.
About BWAY
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains t... [Read more...]
| Industry Diagnostics & Research | IPO Date Apr 17, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol BWAY |
Financial Performance
In 2019, Brainsway's revenue was $23.10 million, an increase of 40.89% compared to the previous year's $16.40 million. Losses were -$10.33 million, 59.4% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Brainsway stock is "Strong Buy." The 12-month stock price forecast is 13.88, which is an increase of 55.61% from the latest price.